Summary
Boston Scientific Corporation reported a net loss of $207 million ($0.15 per share) for the second quarter of 2016, a significant change from the net income of $102 million ($0.08 per share) in the same period last year. This downturn was heavily influenced by substantial litigation-related charges amounting to $618 million. Despite the net loss, the company saw a robust increase in net sales, up 15% year-over-year to $2.126 billion, driven by strong performance across its key segments, particularly Urology and Pelvic Health, which benefited from the acquisition of the AMS Portfolio Acquisition. Excluding significant charges such as litigation, restructuring, and amortization, the company's adjusted net income for the quarter was $373 million, or $0.27 per share, indicating underlying operational strength. For the first half of the year, net sales increased by 13% to $4.090 billion, while the reported net loss was $5 million ($0.00 per share), again impacted by significant charges. The company's cash flow from operations improved significantly, turning positive to $537 million for the first half of 2016 compared to a negative $137 million in the prior year's comparable period, signaling better operational cash generation.
Financial Highlights
52 data points| Revenue | $2.13B |
| Cost of Revenue | $639.00M |
| Gross Profit | $1.49B |
| SG&A Expenses | $779.00M |
| Operating Expenses | $1.82B |
| Operating Income | -$334.00M |
| Interest Expense | $59.00M |
| Net Income | -$207.00M |
| EPS (Basic) | $-0.15 |
| EPS (Diluted) | $-0.15 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Net sales increased by 15% to $2.126 billion in Q2 2016 compared to Q2 2015, showing strong top-line growth.
- 2Reported a net loss of $207 million in Q2 2016, largely due to $618 million in litigation-related charges, a significant shift from a net income of $102 million in Q2 2015.
- 3Urology and Pelvic Health segment experienced substantial growth, up 89% year-over-year, driven by the integration of the AMS Portfolio Acquisition.
- 4Cash flow from operating activities improved significantly, turning positive to $537 million for the first half of 2016, compared to a negative $137 million in the same period of 2015.
- 5Despite the GAAP net loss, adjusted net income was $373 million ($0.27 per share) for Q2 2016, highlighting underlying operational profitability excluding specific charges.
- 6The company's debt levels remain significant, with total debt at $5.427 billion as of June 30, 2016, though leverage ratios remain well within covenant requirements.
- 7Restructuring plans initiated in 2016 and 2014 are expected to yield significant cost savings, with $19 million and $249 million incurred to date respectively.